KuDa

The project:

KUSUDAMA Therapeutics SL is a technology-based spin-off from CIDETEC with the objective of developing new drug formulations for the treatment of a variety of pulmonary conditions. Its technology is based on a nanomedicine platform, known as KuDa, based on a patented methodology for manufacturing single chain nanoparticles (SCNP) by cross-linking the polymer chain with a bifunctional agent in aqueous media at room temperature and in the absence of catalysts.

The objective of this project is the development and scale-up of KuDa-tob, a new formulation of tobramycin with KuDa as excipient, up to preclinical phases for its use as treatment for cystic fibrosis patients affected by chronic pulmonary infections.

CIDETEC’S role in the project:

CIDETEC Nanomedicine leads the CMC (chemistry, manufacturing, and control) part of KuDa-tob development, which involves the design of the formulation following quality by design principles, selection of its pharmaceutical form, the development of analytical methods for quality control, and its production at mid-scale for preclinical studies.